AU2018219895C1 - Engineered Natural Killer (NK) cells and compositions and methods thereof - Google Patents

Engineered Natural Killer (NK) cells and compositions and methods thereof Download PDF

Info

Publication number
AU2018219895C1
AU2018219895C1 AU2018219895A AU2018219895A AU2018219895C1 AU 2018219895 C1 AU2018219895 C1 AU 2018219895C1 AU 2018219895 A AU2018219895 A AU 2018219895A AU 2018219895 A AU2018219895 A AU 2018219895A AU 2018219895 C1 AU2018219895 C1 AU 2018219895C1
Authority
AU
Australia
Prior art keywords
cell
engineered
cells
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018219895A
Other languages
English (en)
Other versions
AU2018219895B2 (en
AU2018219895A1 (en
Inventor
Guy Dipierro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indapta Therapeutics Inc
Original Assignee
Indapta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indapta Therapeutics Inc filed Critical Indapta Therapeutics Inc
Publication of AU2018219895A1 publication Critical patent/AU2018219895A1/en
Publication of AU2018219895B2 publication Critical patent/AU2018219895B2/en
Application granted granted Critical
Publication of AU2018219895C1 publication Critical patent/AU2018219895C1/en
Priority to AU2024227637A priority Critical patent/AU2024227637A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018219895A 2017-02-09 2018-02-08 Engineered Natural Killer (NK) cells and compositions and methods thereof Active AU2018219895C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227637A AU2024227637A1 (en) 2017-02-09 2024-10-25 Engineered natural killer (nk) cells and compositions and methods thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762457098P 2017-02-09 2017-02-09
US62/457,098 2017-02-09
US201762484350P 2017-04-11 2017-04-11
US62/484,350 2017-04-11
PCT/US2018/017493 WO2018148462A1 (en) 2017-02-09 2018-02-08 Engineered natural killer (nk) cells and compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227637A Division AU2024227637A1 (en) 2017-02-09 2024-10-25 Engineered natural killer (nk) cells and compositions and methods thereof

Publications (3)

Publication Number Publication Date
AU2018219895A1 AU2018219895A1 (en) 2019-08-29
AU2018219895B2 AU2018219895B2 (en) 2024-07-25
AU2018219895C1 true AU2018219895C1 (en) 2024-10-03

Family

ID=63107061

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018219895A Active AU2018219895C1 (en) 2017-02-09 2018-02-08 Engineered Natural Killer (NK) cells and compositions and methods thereof
AU2024227637A Pending AU2024227637A1 (en) 2017-02-09 2024-10-25 Engineered natural killer (nk) cells and compositions and methods thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227637A Pending AU2024227637A1 (en) 2017-02-09 2024-10-25 Engineered natural killer (nk) cells and compositions and methods thereof

Country Status (7)

Country Link
US (2) US11920156B2 (https=)
EP (1) EP3580341A4 (https=)
JP (2) JP2020507349A (https=)
CN (1) CN110546265A (https=)
AU (2) AU2018219895C1 (https=)
CA (1) CA3052473A1 (https=)
WO (1) WO2018148462A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
EP4474391A3 (en) * 2018-05-14 2025-02-26 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CN114736859B (zh) * 2022-06-13 2022-08-19 广东先康达生物科技有限公司 一种脐带血nk细胞的培养液及培养方法
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
CN119280423A (zh) * 2024-10-10 2025-01-10 中南大学 一种联合靶向鼻咽癌治疗的载药体系及其制备方法与应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US6635472B1 (en) 1997-08-15 2003-10-21 Rubicon Laboratory, Inc. Retrovirus and viral vectors
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1058500A4 (en) 1998-02-27 2002-05-08 Gen Hospital Corp The helios gene
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6168991B1 (en) 1999-06-25 2001-01-02 Lucent Technologies Inc. DRAM capacitor including Cu plug and Ta barrier and method of forming
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US6723316B2 (en) 1999-12-22 2004-04-20 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
US20030044386A1 (en) 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
NZ537255A (en) 2002-06-21 2009-04-30 Wellstat Biologics Corp Administration of therapeutic viruses
JP2005537802A (ja) 2002-09-09 2005-12-15 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション ラブドウイルスの組み換え型変異体及びその使用方法
DE602004018284D1 (de) 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
EP1644492B1 (en) 2003-06-18 2009-01-07 Genelux Corporation Modified recombinant vaccinia viruses, uses thereof
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
WO2005118854A1 (en) 2004-06-01 2005-12-15 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
JP5525689B2 (ja) 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
CN101495126B (zh) 2005-06-23 2016-01-06 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
EP2114420B1 (en) 2007-02-16 2016-01-27 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
WO2008133938A2 (en) * 2007-04-26 2008-11-06 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
WO2009011924A1 (en) 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
JP5282040B2 (ja) 2007-09-28 2013-09-04 オリンパス株式会社 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
US20090136917A1 (en) 2007-10-25 2009-05-28 Szalay Aladar A Systems and methods for viral therapy
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009139921A2 (en) 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US8877182B2 (en) 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) * 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
US20170137784A1 (en) 2015-03-23 2017-05-18 Cellex Corporation NK Cell Culture Container And NK Cell Culture Method
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
ES2970269T3 (es) 2015-07-29 2024-05-27 Onk Therapeutics Ltd Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A4 (en) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
CN109844099B (zh) 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
EP4474391A3 (en) 2018-05-14 2025-02-26 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
CN109652379B (zh) 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
JP7629414B2 (ja) 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ

Also Published As

Publication number Publication date
JP2020507349A (ja) 2020-03-12
WO2018148462A1 (en) 2018-08-16
JP2023089054A (ja) 2023-06-27
EP3580341A1 (en) 2019-12-18
US11920156B2 (en) 2024-03-05
US12564739B2 (en) 2026-03-03
AU2018219895B2 (en) 2024-07-25
EP3580341A4 (en) 2020-11-04
AU2024227637A1 (en) 2024-11-14
CA3052473A1 (en) 2018-08-16
CN110546265A (zh) 2019-12-06
US20240294874A1 (en) 2024-09-05
US20190376036A1 (en) 2019-12-12
AU2018219895A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2018219895B2 (en) Engineered Natural Killer (NK) cells and compositions and methods thereof
US20250230217A1 (en) Methods for improving the efficacy and expansion of immune cells
JP2026048701A (ja) キメラ抗原受容体発現細胞を作製する方法
JP7280827B2 (ja) Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
US20240316102A1 (en) Engineered natural killer (nk) cells and related methods
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
JP2019531074A (ja) マイナー組織適合性（ｈ）抗原ｈａ−１に特異的なｔｃｒ及びその使用
US12448426B2 (en) Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
JP2021515558A (ja) 二量体抗原受容体（ｄａｒ）
CN113891934A (zh) 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
AU2022301099A1 (en) Antigen-binding polypeptide targeting b7h3 and application thereof
KR20250060188A (ko) 조작된 자연 살해(nk) 세포 및 항체 요법의 조합 및 관련 방법
US20230340067A1 (en) Methods of generating an activation inducible expression system in immune cells
CN117460742A (zh) 用于增强的干细胞样记忆t细胞工程化的材料和方法
JP2026074087A (ja) 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
Štach Enhancing Anti-tumor Efficacy and Improving Manufacturing of Chimeric Antigenic Receptor T Cells
KR20230142760A (ko) Car t 세포 의약품의 제형 및 프로세스
CN118406653A (zh) 腹水来源的修饰的巨噬细胞
HK40124206A (zh) 用於抑制hhv-6感染的体外方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2024

FGA Letters patent sealed or granted (standard patent)